Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O94804
UPID:
STK10_HUMAN
Alternative names:
Lymphocyte-oriented kinase
Alternative UPACC:
O94804; A6ND35; B2R8F5; B3KMY1; Q6NSK0; Q9UIW4
Background:
Serine/threonine-protein kinase 10, also known as Lymphocyte-oriented kinase, plays a pivotal role in the regulation of lymphocyte migration. It achieves this by phosphorylating MSN and potentially PLK1, alongside mediating the phosphorylation of ERM proteins such as MSN. This kinase acts as a negative regulator of MAP3K1/MEKK1 and may serve as a cell cycle regulator by acting as a polo kinase kinase, suggesting its involvement in phosphorylating PLK1.
Therapeutic significance:
Given its involvement in Testicular germ cell tumor (TGCT), a prevalent malignancy in males, understanding the role of Serine/threonine-protein kinase 10 could unveil novel therapeutic strategies. Its regulatory functions in cell migration and cycle may offer insights into targeting TGCT progression.